Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure (NCT04262830)
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
🩺 Plain-English Summary (8th-Grade Level)
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Who can join: Review the eligibility criteria below.
Location: Rady Children's Hospital — San Diego, California
Age range: 13 Years to 39 Years
🧪 Interventions in This Study
- Cardiac magnetic resonance imaging (MRI) (DIAGNOSTIC_TEST)
- Accelerometer physical activity monitoring (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rady Children's Hospital — San Diego, California
📞 Contact the Study Coordinator
Phone: 8589665855 / 8589331718
Email: hnarayan@rchsd.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cardiotoxicity
- Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy — Birmingham, Alabama
- Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) — Minneapolis, Minnesota
- S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity — Anchorage, Alaska
Explore by condition: All Cardiotoxicity clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.